As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development. In order for them to thrive, it is essential that they find the right partner to develop fit-for-purpose bioanalytical methods that can be qualified and validated. Scorpius demonstrates the breadth of expertise and the experienced track record necessary to assist customers on their bioanalytical development journeys.
Strong Demand for Pharmaceutical Analytical Services
Rapid growth in demand across the biopharmaceutical industry continues to drive ongoing efforts to outsource pharmaceutical development and manufacturing, both for more conventional engineered proteins and antibodies and for next-generation antibody-based products and cell and gene therapies. Emerging companies, which are steadily increasing in number but typically have minimal internal resources, rely heavily on service partners to provide specialized support, such as analytical method development. Major biopharma drug developers are also focusing on drug discovery and other areas of core expertise and turning to analytical service providers to supplement their core capabilities.
As a result, various market research firms estimate the value of the global pharmaceutical analytical testing market to be expanding at a compound annual growth rate in the range of 7–10%, rising from approximately $7–7.5 billion in 2021 to $10–11 billion by 2026.1,2 Part of this growth can be attributed to the demand for analytical services in support of the development of COVID-19 vaccines and therapeutics, which will decline over time. That demand will be replaced, however, with demand for support by companies developing novel RNA products; developers of cell and gene therapies, multi-specifics, and antibody conjugates; and producers of engineered protein and antibody products developed against novel drug targets. They will all be looking for varying levels of assistance across all stages of drug development.
Build on Any Existing Assays
Involve the Customer
Key Assay Aspects
Stability is the Key
The Role of Comparative Studies
Rapidly Expanding to Meet Future Customer Needs
Cancer biology is an example of a space that is rapidly evolving and leading to the development of novel immunoassays, some of which are highly specialized. We recognize the importance of this field and the need to develop capabilities in this area to support customers developing these novel drugs. We will soon be incorporating many new immuno-oncology assays (e.g., immune-mediated tumor killing, complement-dependent cytotoxicity, immune checkpoint binding, and functional assays, mixed lymphocyte reaction, T cell invasion, activation, proliferation, and exhaustion) into our offerings in order to continue to support our customers with the bioanalytical solutions they require.
But Remaining Focused on the Customer
Despite the fact that Scorpius is expanding very rapidly, we remain focused on our customers and staying within our general scope of work. We do track new assay technologies and, when they fit within the scope of Scorpius’ business strategies, adopt and implement them to improve the efficiency and effectiveness of our bioanalytical services.
1. Pharmaceutical Analytical Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027). Mordor Intelligence. n.d.
2. Global Pharmaceutical Analytical Testing Outsourcing Industry to Cross $11 Billion by 2027. Research and Markets. 14 Dec. 2021.
BACK TO INDEX